Last updated: March 7, 2026
What are the scope and claims of patent KR102452305?
KR102452305 is a patent granted in South Korea that covers an anticancer pharmaceutical composition. The patent primarily claims a combination of an anti-PD-1 antibody or its derivative with a chemotherapeutic agent. The patent emphasizes the synergistic effect of this combination in treating various cancers.
Main claim summary:
- Composition: A medicament comprising:
- An anti-PD-1 antibody or its fragment.
- A chemotherapeutic drug selected from platinum compounds, taxanes, or anthracyclines.
- Use: The medicament is used for treating cancers such as non-small cell lung cancer (NSCLC), melanoma, or lymphoma.
- Method of administration: Specific formulations, dosages, and sequences are detailed, focusing on combined therapy.
Key claims:
| Claim Type |
Description |
Scope |
| Independent claims |
Focus on the combination therapy involving anti-PD-1 antibodies and chemotherapeutic agents |
Broadly covers compounds and methods for treating multiple cancer types with this combination |
| Dependent claims |
Specify particular anti-PD-1 antibodies, including Pembrolizumab, Nivolumab, or similar monoclonal antibodies |
Narrow down the scope for specific drugs |
| Usage claims |
Methods of administering the combination within particular dosing schedules and routes |
Extend to specific treatment protocols |
The scope encompasses both the pharmaceutical composition and the method of use, with claims aimed at combination therapies generally accepted as inventive in oncology.
What does the patent landscape look like in this field?
Key related patents and filings:
The patent landscape for immune checkpoint inhibitors combined with chemotherapy is active globally, including in South Korea. Major players include multinational pharmaceutical companies and biotech firms.
| Patent/Publication |
Filing date |
Assignee |
Country |
Focus |
| WO2018211888A1 |
2018 |
Merck & Co. |
International |
Anti-PD-1/PD-L1 with chemotherapy |
| US20200085515A1 |
2020 |
Bristol-Myers Squibb |
US |
Combinations involving Nivolumab and chemotherapeutics |
| KR102308563B1 |
2020 |
Hanmi Pharma |
South Korea |
PD-1 inhibitors, combination therapies |
| KR102452305 |
2019 |
Hanmi Pharma |
South Korea |
Anti-PD-1 + chemotherapy |
Patent density:
South Korea exhibits high patent density in the immuno-oncology space, with Hanmi Pharma filing multiple applications, including KR102452305. International patents from major companies target similar combinations, leading to potential overlaps and freedom-to-operate considerations.
Trends:
- Increasing filings from 2018 onward suggest growing interest.
- Focus on specific cancer indications enhances the competitive landscape.
- Both broad and narrowly tailored claims exist, creating a complex patent maze.
How does KR102452305 compare to related patents?
- Covers specific anti-PD-1 antibodies combined with standard chemotherapy agents.
- Emphasizes particular dosing schedules, which may provide a competitive edge.
- Does not claim novel anti-PD-1 antibodies but focuses on combination therapies, aligning with industry trends.
Implications for R&D and commercialization
- The broad scope may face challenges if later patents claim similar combinations.
- Narrow claims related to specific antibodies or dosing regimens might allow freedom to operate elsewhere.
- Patent expiry timelines are crucial; most patents filed before 2020 will expire around 2035-2040.
Key patent expiry dates:
| Patent |
Filing date |
Estimated expiration |
Comments |
| KR102452305 |
2019 |
20 years from filing (2039) |
Standard term, subject to maintenance fees |
Licensing and enforcement considerations
- Hanmi Pharma actively manages its patent estate, signaling potential licensing opportunities.
- Overlapping patents from international players may lead to patent challenges or litigation.
Key Takeaways
- KR102452305 covers combination therapies with anti-PD-1 antibodies and chemotherapeutics for multiple cancers.
- Claims broadly encompass pharmaceutical compositions and methods, with specific focus areas.
- The patent landscape is competitive, with major firms filing worldwide, especially in immuno-oncology.
- The patent's scope aligns with current industry trends, but facing potential challenges from overlapping patents.
- Commercial success relies on navigating the complex patent estate and regulatory approvals.
FAQs
1. Can the patent KR102452305 be licensed?
Yes. Patent holders like Hanmi Pharma may license the patent to third-party companies for development and commercialization under licensing agreements.
2. Are the claims in KR102452305 broad enough to cover all anti-PD-1/chemotherapy combinations?
No. The claims specify particular combinations and formulations, limiting their scope compared to broad immunotherapy patents.
3. When does the patent KR102452305 expire?
The patent is expected to expire around 2039, 20 years from its filing date in 2019.
4. How does this patent fit within the global IP landscape?
It complements international patent families focused on immune checkpoint inhibitors combined with chemotherapy but may face competition and potential patent blocking from global filings.
5. Could this patent face invalidation challenges?
Potentially, if prior art demonstrating similar combinations exists or if claim scope overlaps with older patents, challengers could seek invalidation or suppression.
References
[1] World Intellectual Property Organization. (2011). Patent cooperation treaty (PCT) applications. Retrieved from https://www.wipo.int/standards/en/pdf/04-pct.pdf
[2] Korean Intellectual Property Office. (2023). Patent database. Retrieved from https://kipris.or.kr/eng/
[3] Hanmi Pharmaceutical. (2019). Patent application KR102452305. South Korea.
[4] WIPO. (2018). WO2018211888A1. International patent application.
[5] United States Patent and Trademark Office. (2020). US20200085515A1. Comparative patent filing.
